Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$26.77 USD
+0.04 (0.15%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $26.76 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.77 USD
+0.04 (0.15%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $26.76 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
PJT Partners (PJT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PJT Partners (PJT) delivered earnings and revenue surprises of 54.69% and 41.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Implied Volatility Surging for Royalty Pharma (RPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Royalty Pharma (RPRX) stock based on the movements in the options market lately.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 21.21% and 23.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Owl Rock Capital Corporation (ORCC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Owl Rock Capital Corporation (ORCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MVB Financial (MVBF) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
MVB Financial (MVBF) delivered earnings and revenue surprises of -65.52% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is PRA Group (PRAA) Down 10.4% Since Last Earnings Report?
by Zacks Equity Research
PRA Group (PRAA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
GBOOY or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma (RPRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 0% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Royalty Pharma (RPRX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Phillips Edison & Company, Inc. (PECO) Q3 FFO and Revenues Top Estimates
by Zacks Equity Research
Phillips Edison & Company, Inc. (PECO) delivered FFO and revenue surprises of 9.43% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Jackson Financial (JXN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up
by Zacks Equity Research
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.28% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?